Endothelial Dysfunction in Pulmonary Hypertension

J.C. Caraballo Fonseca, C.D. Martínez Balzano, and R. Sánchez de León

Sección de Fisiología Respiratoria, Facultad de Medicina, Escuela de Medicina Luis Razetti, Universidad Central de Venezuela, Caracas, Venezuela.

Pulmonary hypertension (PH) is a heterogeneous disease characterized by a pulmonary arterial pressure of more than 20 mm Hg at rest or 30 mm Hg during exercise that is usually due to an increase in pulmonary vascular resistance and in its later stages leads to heart failure. It occurs in 2 forms: primary and secondary. While the cause of primary PH is not fully understood, secondary PH is known to occur with a variety of diseases, such as chronic thromboembolism, collagen vascular diseases, mitral valve disease, vasoconstriction due to hypoxia, infection with the human immunodeficiency virus, and certain drugs (anorexiants).1 All types of PH, both primary and secondary, have similar clinical manifestations.

Primary PH has a prevalence of 1 case per 1 000 000 individuals and is more common in women than men (a 1.7 to 1 ratio).2 It is often hereditary and can affect multiple members of the same family; in this case it is known as familial primary PH. Cases in which there is no evidence of family history of the disease are classified as sporadic or nonfamilial primary PH. Primary PH is normally diagnosed in advanced stages, since earlier symptoms are nonspecific; consequently, the detailed natural history of the disease remains unknown. Patient survival ranges from 6 months to 3.5 years after diagnosis, depending on the New York Heart Association (NYHA) functional classification. The majority of patients die as a result of heart failure and sudden death.2

The pathophysiology of PH largely depends upon whether it is primary or secondary. Primary PH has traditionally been thought to develop in response to an as yet unidentified defect that leads to an imbalance between the different vasoactive agents that act on the smooth muscle of the pulmonary vasculature. This imbalance leads to a predominance of vasoconstriction, the consequence of which is an increase in vascular resistance and, therefore, pulmonary arterial pressure. In the long term, morphological changes in the arterial wall occur (Figure). It is well known that the endothelium is responsible for the production of these vasoactive agents, which act on the medial layer of the arteries. Consequently, any alteration in these mediators must be a product of altered endothelial function. Vascular remodeling is almost identical in primary and secondary PH. It is characterized by proliferation of the medial layer, thickening of the intimal layer, and the formation of plexiform lesions, which constitute a mass of disorganized vessels containing proliferating endothelial cells, myofibroblasts, and smooth muscle cells. In primary PH, these lesions are more commonly found in the small arteries and arterioles, along with obstructive

Correspondence: Dr. R. Sánchez de León.
POBA international #1-20312, Miami, Florida 33102-5255, USA.
E-mail: rsdl@telcel.net.ve

Manuscript received August 24, 2004. Accepted for publication October 18, 2004.

Figure. Flow chart showing the pathophysiology of pulmonary hypertension. Endothelial dysfunction and the resulting imbalance in vasoactive substances that this generates are central to the pathophysiology of primary pulmonary hypertension. Ang-1 indicates angiopoietin-1; ET_{1}, endothelin-1; NO, nitric oxide; PGI_{2}, prostacyclin; HHV-8, human herpesvirus type 8.
intimal thickening. In the primary disease, plexiform and concentric lesions contain a monoclonal population of endothelial cells; however, this is not the case in secondary PH. This suggests that there may be a genetic alteration in these cells that leads to their proliferation in primary PH. Humoral signals arising from these defective endothelial cells would be responsible for the altered vascular tone and the development of the characteristic pathology of primary PH. However, it is also possible that these lesions represent an inappropriate response of the vasculature to increased pressure.

The genetics of familial primary PH have been extensively studied and an autosomal dominant pattern of inheritance has been observed. The disease is manifested in 10% to 20% of individuals who carry the mutation and, in addition, each new generation of carriers manifests the disease at an earlier age, a finding that is consistent with the phenomenon of genetic anticipation. The mutation responsible for many cases of familial primary PH has been localized to the 2q31-q32 locus in the gene that codes for bone morphogenetic protein receptor type II (BMPR-II). This gene encodes a receptor for proteins of the transforming growth factor beta (TGF-β) superfamily, which contains both TGF-β itself and the bone morphogenetic proteins (BMPs). These growth factors regulate the differentiation and apoptosis of many cell types, including vascular smooth muscle, mainly by inhibiting growth and proliferation. Consequently, BMPR-II dysfunction would interfere with the antiproliferative signal provided by TGF-β superfamily members in the smooth muscle of the pulmonary vasculature and would, therefore, contribute to the alterations observed in the medial layer in primary PH. Mutations have also been described in the gene ALK1, which codes for the type I TGF-β receptor, in individuals with PH and hereditary hemorrhagic telangiectasia. Nevertheless, there are many cases of familial primary PH in which mutations have not been identified in either of these 2 genes, indicating the existence of other mechanisms, probably involving mutations in genes associated with the TGF-β superfamily, such as the Smads, proteins responsible for intracellular signaling downstream of BMPR-II. It is likely that these mutations, along with many others that remain to be characterized, not only have a direct effect on the response of the smooth muscle to growth factors such as TGF-β but also make the tissue more susceptible to paracrine signals from an endothelium that is altered, largely as a result of genetic defects. This would trigger a series of events that would culminate in the establishment of PH and vascular remodeling.

One of the most important vasoactive agents implicated in PH is endothelin-1 (ET1), the most potent vasoconstrictor identified to date. ET1 is a 21-amino acid peptide produced by the endothelium that acts through its receptors ETA and ETB to activate voltage-dependent Ca2+ channels. Under normal conditions, ET1 is secreted in limiting quantities by the pulmonary vasculature. Patients with PH, however, have a clearly increased production of ET1, that is directly correlated with the severity of the disease and the extent of development of plexiform lesions; thus, functional alteration of the endothelium would generate a larger amount of ET1, and this increased production would be largely responsible for the increase in pulmonary vascular resistance through its action as a potent vasoconstrictor. In addition, ET1 is linked to the induction of vascular remodeling by causing an increase in the expression of the serotonin 1B receptor in vascular smooth muscle cells. This is supported by the beneficial effects of treatment with ET1-receptor antagonists, such as bosentan and sitaxsentan. Studies that have considered groups of PH patients in different NYHA functional classes subjected to short-term and long-term treatment with bosentan have provided very encouraging results, with a clear clinical improvement and a slight remission of vascular remodeling. This demonstrates the importance of ET1 in the pathophysiology of hypertension and, it would seem, the process of vascular remodeling in PH.

Various authors have attempted to relate certain pathophysiologic events common to the majority of patients with nonfamilial PH in a basic scheme to explain the development of the disease. Thus, angiotensin-1 (Ang-1), a hormone secreted during embryonic vascular development that is not normally detected in adult life, is found at increased levels in the blood of patients with primary PH and the level is known to be directly proportional to the clinical severity of the disease. These same patients display enhanced phosphorylation of the TIE-2 receptor, a receptor for Ang-1 that is exclusively expressed in endothelial cells, and reduced expression of the BMP1A receptor; patients with familial primary PH also have reduced levels of BMP1A due to the fact that the defective BMPR-II has a tendency to dimerize with it. It has been demonstrated in vitro that these effects are directly attributable to Ang-1, and in vivo Ang-1 induces muscular hyperplasia in the pulmonary arterioles. That study showed that Ang-1 acts via TIE-2 signaling to promote endothelial release of serotonin, a potent stimulator of growth in the smooth muscle cells that form the medial layer of blood vessels; this growth is not observed when serotonin receptors are blocked. Furthermore, serotonin levels are increased in the intimal and medial layers of the pulmonary arteries of patients with PH but not in healthy subjects, in whom the expression levels are very low. These findings suggest that defective production of Ang-1 could also be one of the pathophysiologic events that are important in PH, be it a constitutive defect, a defect caused by external factors, or perhaps a combination of the two.

Nitric oxide (NO) is another vasoactive agent synthesized by the endothelium that has been linked to the pathophysiology of PH as a result of its important role as a vasodilator. It is synthesized from L-arginine...
by NO synthase, which exists in 3 isoforms: an isoform, expressed mainly by macrophages, another isoform expressed by neurons, and an endothelial form. Endothelial NO synthase (eNOS) is dependent on calcium and is widely expressed in the pulmonary endothelium of healthy individuals. Its action has been implicated in the maintenance of low resistance in the pulmonary vascular circuit and its metabolism is clearly altered in patients with PH. NO acts through cyclic guanosine monophosphate (cGMP) to regulate potassium channels. Sildenafil, an inhibitor of type 5 cGMP-specific phosphodiesterase, has been beneficial in the treatment of PH and has even been used as a substitute for the subcutaneous prostacyclin analog treprostinil in the treatment of a case of PH associated with lupus erythematosus. The metabolism of NO is altered in patients with PH, as shown by reduced levels of eNOS in lung tissue from patients with the disease. There is a consequent reduction in the production of NO, the extent of which is directly correlated with the degree of vascular resistance and the clinical stage of the disease. This supports the possibility that the main vasodilator that is reduced in PH is NO.

The link between NO and pulmonary hypertension has traditionally been accepted. However, recent evidence has indicated that plexiform lesions have increased expression of eNOS, leading to the hypothesis that there is a compensatory mechanism associated with increased vascular tone in PH. Paradoxically, increased expression of the enzyme is not always accompanied by a concomitant increase in NO production. In addition, levels of inducible NO synthase, which had not been studied previously, were revealed in this study to be increased in the plexiform lesions of patients with PH, probably in relation to shear stresses. This study was limited by the fact that immunohistochemical methods can demonstrate increased expression of a protein but not its degree of activation, thereby leaving doubts over whether the endothelium expresses a defective form of the enzyme, probably as a result of a mutation, that triggers defective production by the endothelium and a consequent deficiency in the medial layer of the vessels that would permit a predominant effect of vasoconstrictors such as ET.

Another important vasoactive agent that could be affected in a dysfunctional endothelium is prostacyclin, which has also been studied in relation to the pathophysiology of PH. Prostacyclin is the principal arachidonic acid metabolite released by the endothelium and possesses both vasodilatory and antiplatelet effects. In normal lungs, prostacyclin synthase is expressed at lower levels in the arterioles and small caliber vessels. This characteristic pattern of expression seems to be exaggerated in patients with PH, probably because the arterioles of these individuals have a greater number of plexiform lesions and more marked endothelial alteration. Consequently, enhanced vasoconstriction and a tendency towards coagulation is seen in these vessels, favoring the chronic thromboembolism present in some patients with PH. The use of prostacyclin (epoprostenol) is currently the most effective treatment for the management of these patients, particularly those in high-risk states. Inhaled iloprost, a stable analog of prostacyclin, has been used to treat secondary PH occurring as a result of chronic thromboembolism in which surgery has been rejected. The results obtained are better than with traditional treatment, not only due to its vasodilatory effects but also to its antiplatelet activity.

Another field of investigation in PH is focused on potassium channels. Comparison of the functionality of these channels in smooth muscle cells from the pulmonary arteries of patients with primary and secondary PH has shown that the potassium channels of cells from patients with primary PH have reduced function. This indicates that the smooth muscle would show an enhanced response to vasoconstrictors released by the endothelium, since they would generate a higher membrane potential and an increased cytoplasmic calcium concentration. This would play a central role in vasoconstriction and could possibly act as a stimulus for hyperplasia and hypertrophy of the vascular smooth muscle in primary PH.

Very recently, Cool et al. used immunohistochemical methods to demonstrate the presence of human herpesvirus type 8 (HHV-8), a vasculotropic virus implicated in Kaposi’s sarcoma, in the lung tissue of 10 patients with primary PH but not in patients with secondary PH. A clear association was found between this virus and primary PH. These interesting findings suggest that HHV-8 infection of the lungs could be a factor that contributes to the monoclonal expansion of endothelial cells and the somatic mutations present in the plexiform lesions of patients with primary PH that would lead to altered endothelial function and, from this point, all of the alterations that favor establishment of the disease.

Despite these findings relating to the etiopathology of primary PH, there still remains much to be understood in terms of the pathophysiology. Nevertheless, the characterization of the pathophysiologic process advances further each day and will lead to new therapeutic options. In reality, endothelial dysfunction is the central pathophysiologic event in primary PH, since all of the implicated processes are either a cause or a consequence. Due to the central role of the endothelium in the regulation of vascular tone, any factor that affects it and its release of vasoactive agents will also affect vascular resistance and, consequently, be a cause of PH. The discovery of the genetic, humoral, and even viral processes that can play an important role in establishing endothelial dysfunction gives us an idea of the complexity of the pathogenesis of this disease and the heterogeneity of the mechanisms involved, all of which make primary PH an incurable and difficult to treat disease. It is hoped that the advances in scientific research in this field will help to resolve this situation.
CARABALLO FONSECA JC, ET AL. ENDOTHELIAL DYSFUNCTION IN PULMONARY HYPERTENSION

REFERENCES